Long-acting injectable antipsychotics: focus on olanzapine pamoate.

Neuropsychiatric Disease and Treatment
Jean-Pierre Lindenmayer

Abstract

Medication non-adherence in patients with schizophrenia continues to be a significant problem and threatens successful treatment outcomes. Medication non-adherence is often associated with negative consequences, including symptom exacerbation, more frequent emergency room visits, re-hospitalizations and relapse. Long-acting injectable (LAI) forms of antipsychotics allow for rapid identification of non-adherence, obviate the need for the patient to take the medication on a daily basis and increase adherence to some significant degree. Eli Lilly has developed a long-acting depot formulation of olanzapine, olanzapine pamoate, which has recently been approved by the FDA for the US market, and which will be reviewed here. Olanzapine LAI appears to be an effective antipsychotic at dosages of 210 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks in patients with acute schizophrenia, and at 150 mg every 2 weeks, 300 mg every 2 weeks and at 405 mg every 4 weeks for the maintenance treatment of stable patients. Oral supplementation appears not to be needed, particularly not at the onset of treatment with the LAI as is necessary with risperidone LAI. Its efficacy is in general comparable to the efficacy seen with oral olanza...Continue Reading

References

Dec 19, 2003·The Journal of Clinical Psychiatry·Stephen R Marder
Mar 16, 2007·Acta Psychiatrica Scandinavica·H A Nasrallah
Apr 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David MamoDavid McDonnell

❮ Previous
Next ❯

Citations

Apr 2, 2013·Archives of Pharmacal Research·Eun Ji ParkDong Hee Na
Nov 10, 2013·The Journal of Emergency Medicine·Dominique VodovarBruno Mégarbane
Nov 15, 2013·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Tor SkomedalStein Opjordsmoen Ilner
Feb 7, 2016·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Naresh MittapellyPrabhat Ranjan Mishra
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Dieter Naber
Sep 13, 2013·Expert Opinion on Drug Safety·Daniel SchöttleDieter Naber
Jan 14, 2016·Expert Opinion on Drug Safety·L SamalinPm Llorca
Sep 9, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Nicolas DarvilleGuy Van den Mooter
Dec 31, 2014·International Journal of Psychiatry in Clinical Practice·Massimo C MauriCarlo A Altamura
Jul 4, 2012·Expert Opinion on Pharmacotherapy·Pierre Chue, James Chue
Aug 10, 2013·The Australian and New Zealand Journal of Psychiatry·Majella Su-Xian ChewBirinder Narang
Oct 30, 2013·Therapeutic Advances in Psychopharmacology·Matthias KirschnerMatthias Jäger
Feb 13, 2019·Clinical Neuropharmacology·Velprashanth VenkatesanM B Deepak
Mar 5, 2019·Expert Opinion on Drug Delivery·Ziwei MaXing Tang
Dec 15, 2012·Expert Review of Neurotherapeutics·Pierre Chue, James Chue
Jul 28, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Lee M TathamAndrew Owen
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura
Nov 17, 2020·Therapeutic Drug Monitoring·Georgios SchoretsanitisChristoph Hiemke
Jun 10, 2011·The New England Journal of Medicine·Shawn G KwatraStephen I Kramer
Jul 24, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Chi-Un PaePrakash S Masand

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved